Overview

Safety of Brimonidine Tartrate Ophthalmic Solution in a Population of Pediatric, Adult, and Geriatric Participants

Status:
Completed
Trial end date:
2014-06-23
Target enrollment:
Participant gender:
Summary
To compare the safety and tolerability of brimonidine tartrate ophthalmic solution 0.025% versus its vehicle in a population of pediatric, adult, and geriatric participants. At least 51% of participants will be 40 years of age or older.
Phase:
Phase 3
Details
Lead Sponsor:
Bausch & Lomb Incorporated
Collaborator:
ORA, Inc.
Treatments:
Brimonidine Tartrate
Ophthalmic Solutions
Pharmaceutical Solutions